Nomura Micro Science has revised its fiscal year 2026 financial results, with operating cash flow adjusted to \u00a54,363 million. Details of net income and cash flow have also been corrected, leading to a reassessment of the financial position.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6254","jir_company_name":"Nomura Micro Science Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/6254-20260616-01.pdf","jir_short_summary":"Nomura Micro Science has revised its fiscal year 2026 financial results, with operating cash flow adjusted to \u00a54,363 million. Details of net income and cash flow have also been corrected, leading to a reassessment of the financial position.","jir_summary":"### Revisions to Financial Results\nNomura Micro Science has corrected certain figures in its fiscal year 2026 financial summary due to previous inaccuracies. Corrections were made to the cash flow amounts, the deferred tax liabilities in fixed liabilities on the consolidated balance sheet, and various items in the cash flow statement. As a result, the end-of-period balance of cash and cash equivalents stands at \u00a59,933 million. These adjustments reflect a reassessment of the company's cash flow and asset-liability position compared to the previous year. The corrections were identified during the audit review process, aiming to ensure precise financial disclosures.\n\n### Financial Status and Future Outlook\nPost-correction financial statements show changes in operating, investing, and financing cash flows, with operating cash flow revised to \u00a54,363 million. Accurate understanding of net income and cash flow is needed to revise management strategies and capital plans. The company intends to continue providing accurate financial disclosures and maintain investor trust.","jir_financial_highlights":"Cash flow from operating activities: \u00a54,363 million (Decreased from \u00a54,679 million in the previous period)\nCash and cash equivalents at end of period: \u00a59,933 million (Decreased compared to the previous year)\nConsolidated cash flow: Adjusted to \u00a54,363 million (Previously \u00a54,679 million)","jir_category":"","jir_hashtags":"#NomuraMicroScience, #EarningsRevision, #JapaneseStocks","jir_key_figures":"Cash flow from operating activities: \u00a54,363 million\nCash and cash equivalents at end of period: \u00a59,933 million\nConsolidated cash flow: \u00a54,363 million","jir_meta_title":"\u3010Nomura Micro Science\u3011 Fiscal Year 2026 Earnings Revision | Cash Flow Adjustment","jir_meta_description":"Nomura Micro Science has revised its fiscal year 2026 financial results, adjusting operating cash flow to \u00a54,363 million. The revision impacts financial status and future management strategies.","jir_og_title":"\u3010Nomura Micro Science\u3011 Earnings Revision | Cash Flow Adjustment","jir_og_description":"An overview of the earnings revision for fiscal year 2026 and the update on financial status. Investors should review the latest financial information.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9560,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-64981","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n